Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Fecal Microbiota Transplantation combined with immune checkpoint inhibitors and Bevacizumab in MSS / pMMR Study on the safety and efficacy of posterior treatment in patients with advanced Colorectal Cancer

ABSTRACT: Interventions: Experimental group:Fecal Microbiota Transplantation combined with Immune Checkpoint Inhibitors and Bevacizumab Primary outcome(s): Changes of intestinal flora quantity;15 immune functions Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2761742 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Colitis associated with immune checkpoint inhibitors

Project description:Colitis associated with immune checkpoint inhibitors

| PRJNA849977 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_cells]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_cells]

| PRJNA849981 | ENA

Colitis associated with immune checkpoint inhibitors [blood_cells]

Project description:Colitis associated with immune checkpoint inhibitors [blood_cells]

| PRJNA849982 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

| PRJNA849980 | ENA

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.

Project description:The introduction of checkpoint inhibitors provided remarkable achievements in several solid tumors but only 5% of metastatic colorectal cancer (mCRC) patients, i.e., those with bearing microsatellite instable (MSI-high)/deficient DNA mismatch repair (dMMR) tumors, benefit from this approach. The favorable effect of immunotherapy in these patients has been postulated to be due to an increase in neoantigens due to their higher somatic mutational load, also associated with an abundant infiltration of immune cells in tumor microenvironment (TME). While in patients with dMMR tumors checkpoint inhibitors allow achieving durable response with dramatic survival improvement, current results in patients with microsatellite stable (MSS or MSI-low)/proficient DNA mismatch repair (pMMR) tumors are disappointing. These tumors show low mutational load and absence of "immune-competent" TME, and are intrinsically resistant to immune checkpoint inhibitors. Modifying the interplay among cancer cells, TME and host immune system is the aim of multiple lines of research in order to enhance the immunogenicity of pMMR mCRC, and exploit immunotherapy also in this field. Here, we focus on the rationale behind ongoing clinical trials aiming at extending the efficacy of immunotherapy beyond the MSI-high/dMMR subgroup with particular regard to academic no-profit studies.

| S-EPMC7465130 | biostudies-literature

Using proteomics and transcriptomics to explore the potential gene regulatory network of immune checkpoint inhibitors-related myocarditis

Project description:Immune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early diagnosis and treatment options, it is of great significance to understand the pathophysiological mechanism of immune checkpoint inhibitor-related myocarditis.

2023-02-02 | PXD039793 |

Faecalibaterium prausnitzii strain EXL01 boosts efficacy of Immune Checkpoint Inhibitors

Project description:Faecalibaterium prausnitzii strain EXL01 boosts efficacy of Immune Checkpoint Inhibitors

| PRJNA983285 | ENA

Transcriptomic studies on ruxolitinib with or without checkpoint inhibitors as a cancer therapy

Project description:Unleashing anti-tumor T cell activity by checkpoint inhibition is effective in many cancer patients but clinical response rates remain limited. Myeloid derived suppressor cells erode antitumor lymphocyte numbers and function, and correlate with resistance to checkpoint inhibitors. By screening small molecule libraries, we identified JAK inhibitors’ ability to rescue T cell function. Despite its documented immune suppressive properties, the prototypical JAK inhibitor ruxolitinib enhanced the efficacy of immune checkpoint blockade in cancer. This effect correlated with loss of suppressive gene expression, and acquisition of immunostimulatory molecular markers and T cell stimulatory activity in myeloid cells. In preclinical models, ruxolitinib significantly improved the function and increased the total numbers of activated tumor-infiltrating NK and CD4 T cells compared to checkpoint blockade alone and the efficacy was conditional on granulocytic cells. In addition to myeloid reprogramming in the tumor, ruxolitinib blunts G-CSF signaling in the bone marrow to prevent expression of suppressive and chemotaxis genes in neutrophils.

2024-06-20 | GSE209647 | GEO

Immune checkpoint inhibitor-induced colitis

Project description:Immune checkpoint inhibitor-induced colitis

| PRJNA857579 | ENA

Single-cell transcriptome profiles of tumor tissues from lung cancer patients receiving immune checkpoint inhibitors.

Project description:We performed single-cell RNA sequencing of lung cancer patients receiving immune checkpoint inhibitors. Tumor signatures and immune cell profiles associated with ICI response were identified in lung cancer.

2024-11-05 | GSE205335 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data